A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

Avagacestat

Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks

DRUG

Placebo

Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks

Trial Locations (64)

2100

Local Institution, Copenhagen

10016

Nyu Langone Medical Center, New York

10032

Columbia University, New York

11235

Spri Clinical Trials, Llc, Brooklyn

14642

University Of Rochester Medical Center, Rochester

20520

Local Institution, Turku

21033

Local Institution, Dijon

27103

Clinical Trials Of America, Inc., Winston-Salem

27157

Wake Forest University School Of Medicine, Winston-Salem

27607

Raleigh Neurology Associates, Pa, Raleigh

27609

Richard H. Weisler, Md, Pa & Assoc., Raleigh

27710

Duke University Medical Center, Durham

31059

Local Institution, Toulouse

32806

Compass Research, Llc, Orlando

33009

Md Clinical, Hallandale

33076

Local Institution, Bordeaux

33445

Brain Matters Research, Delray Beach

34601

Meridien Research, Brooksville

35033

Local Institution, Rennes

35294

University Of Alabama At Birmingham, Birmingham

42003

Four Rivers Clinical Research, Inc, Paducah

43210

The Ohio State University, Columbus

43623

Neurology & Neuroscience Center Of Ohio, Toledo

44093

Local Institution, Nantes

46202

Indiana University Medical Center, Indianapolis

53226

Mcw Clinics At Froedtert Hospital, Milwaukee

53562

Dean Foundation For Health Research & Education, Middleton

63104

St Louis University, St Louis

63108

Washington University School Of Medicine, St Louis

74104

Tulsa Clinical Research, Llc, Tulsa

75390

The University Of Texas, Dallas

78757

Senior Adults Specialty Research (Sasr), Austin

80239

Radiant Research, Inc., Denver

85004

21st Century Neurology, Phoenix

85006

Banner Alzheimer'S Institute, Phoenix

85351

Sun Health Research Institue, Sun City

85381

Pivotal Research Centers, Peoria

89106

Cleveland Clinic Lou Ruvo Center For Brain Health, Las Vegas

90095

Mary S. Easton Center, Los Angeles

90806

Collaborative Neuroscience Network, Inc., Long Beach

91403

California Neuroscience Research Medical Group, Inc., Sherman Oaks

92103

Pacific Research Network, San Diego

92108

Affiliated Research Institute, San Diego

92161

University Of California, San Diego, San Diego

92660

Pharmacology Research Institute, Newport Beach

92868

Uc Irvine Medical Center, Orange

93720

Margolin Brain Institute, Fresno

97225

Providence Cognitive Assessment Clinic, Portland

97239

Oregon Health & Science University, Portland

06510

Yale University School Of Medicine, New Haven

06360

Comprehensive Psychiatric Care, Norwich

02115

Brigham & Women'S Hospital, Boston

07724

Memory Enhancement Center Of Amercia, Inc., Eatontown

08903

Robert Wood Johnson Medical School, Umdnj, New Brunswick

08540

Global Medical Institutes, Llc, Princeton

08755

Memory Enhancement Center Of Nj, Inc., Toms River

02906

Butler Hospital, Providence

T2N 4Z6

Local Institution, Calgary

V6T 2B5

Local Institution, Vancouver

N6C 5J1

Local Institution, London

M5T 2S8

Local Institution, Toronto

J4V 2J2

Local Institution, Greenfield Park

431 41

Local Institution, Mölndal

141 86

Local Institution, Stockholm

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00890890 - A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease | Biotech Hunter | Biotech Hunter